Engineered immune cells take on Hard-to-Treat blood cancers
NCT ID NCT05797233
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-phase trial tests a new treatment for people with B-cell cancers (like leukemia or lymphoma) that haven't improved with standard therapies. The approach uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to see if this treatment is safe and feasible, with follow-up for up to 15 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a single shot build a cancer army inside the body?
- Can a Two-Drug combo wipe out hidden leukemia cells?